Printer Friendly

ENDOTRONICS, INC. INTRODUCES ACUMOUSE CELL CULTURE INSTRUMENT -- COST-EFFECTIVE SUBSTITUTE FOR LABORATORY MICE

 ENDOTRONICS, INC. INTRODUCES ACUMOUSE CELL CULTURE INSTRUMENT --
 COST-EFFECTIVE SUBSTITUTE FOR LABORATORY MICE
 MINNEAPOLIS, Dec. 10 /PRNewswire/ -- Endotronics, Inc. (NASDAQ: ENDO) announced today at the American Society of Cell Biology Conference (ASCB) in Boston, the introduction of its new ACUMOUSE(TM) cell culture system. This revolutionary tool for biotechnology research is designed to replace laboratory mice as a source of monoclonal antibodies, which are used for a variety of applications including research into treatments for cancer, AIDS, hepatitis and other diseases.
 Richard E. Sakowicz, president and chief operating officer of Endotronics, said: "We are very excited about what the ACUMOUSE means for the biotechnology industry. For the first time, researchers will have a cost-effective alternative to using ascites (mice) as a source of monoclonal antibodies for research quantities. This is timely, given the growing strength of the animal rights movement worldwide. The ACUMOUSE is also the first Endotronics system to incorporate our advanced Oxycell(TM) bioreactor technology." Sakowicz explained that the proprietary Oxycell technology "overcomes scalability limitations of earlier technologies by allowing optimal delivery of oxygen directly to the cell mass."
 "We expect the ACUMOUSE system to have a significant impact on our worldwide sales over the next five years. Initial delivery of the ACUMOUSE will begin during the spring of 1992," Sakowicz said. "The ACUMOUSE system and the Oxycell technology is the cornerstone of our growth strategy, as we expand and diversify our cell culture products and services."
 Endotronics, Inc., headquartered in Minneapolis, is a recognized industry leader in hollow fiber cell culture instrumentation. With more than 650 instruments installed worldwide, the company's products and services are used by biotechnology, pharmaceutical, and diagnostic companies and research centers for production of mammalian cell-derived human health care products.
 -0- 12/10/91
 /CONTACT: Yvonne L. Bova of Endotronics, Inc., 313-871-7350/
 (ENDO) CO: Endotronics, Inc. ST: Minnesota IN: MTC SU: PDT


JG -- DE006 -- 0943 12/10/91 10:37 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 10, 1991
Words:317
Previous Article:CHESAPEAKE CORPORATION DECLARES DIVIDEND
Next Article:THE MEXICO FUND DECLARES DIVIDEND
Topics:


Related Articles
UNIVERSITY OF MINNESOTA AND ENDOTRONICS, INC. TO COLLABORATE ON DEVELOPMENT OF BIO-ARTIFICIAL DEVICE TO REPLACE LIVER FUNCTION
ENDOTRONICS DISCONTINUES DISTRIBUTION AGREEMENT WITH VENTREX LABORATORIES -- SIGNS LETTER OF INTENT WITH NORTHUMBRIA BIOLOGICALS
ENDOTRONICS, INC. RECEIVES U.S. PATENT ON SCALABLE OXYCELL CELL CULTURE TECHNOLOGY
ENDOTRONICS, INC. REPORTS RESULTS FOR FIRST QUARTER ENDED DEC. 31, 1991
ENDOTRONICS, INC. RECEIVES $1 MILLION PURSUANT TO INVESTMENT AGREEMENT WITH INTEGRA HOLDING AG OF SWITZERLAND
ENDOTRONICS SIGNS PRODUCTION AND MARKETING AGREEMENT WITH HELIXYS
ENDOTRONICS, INC. CONFIRMS SCIENTIFIC ADVISORY BOARD FOR BIO-ARTIFICIAL LIVER PROJECT
ENDOTRONICS, INC. AGREES TO PURCHASE VERAX PRODUCT LINE
CELOX CORPORATION FILES TRADEMARK SUIT AGAINST FORMER ENDOTRONICS
CELLEX BIOSCIENCES Introduces LSL Biolafitte Prelude A New Benchtop Stirred Tank System

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters